Edit filter log

'@@ -22,5 +22,5 @@ | website = {{URL|https://www.biopharma.com.ua/en/home-page/}} }} -'''Biopharma LLC''' (Ukrainian: ТОВ «Фармацевтичний завод “Біофарма”») is a [[ukraine|ukrainian]] [[Pharmaceutical industry|pharmaceutical]] company focused on the development and production of [[drug]]s based on human [[Blood plasma|plasma]]. +'''Biopharma LLC''' (Ukrainian: ТОВ «Біофарма плазма») is the [[ukraine|Ukrainian]] [[Pharmaceutical industry|pharmaceutical]] company focused on the development and production of [[drug]]s based on human [[Blood plasma|plasma]]. == History == @@ -30,9 +30,9 @@ === 20th century === -In 1920, with the opening of [[Epidemiology|epidemiological]], [[Microbiology|microbiological]], [[Parasitology|parasitological]] and sanitary-hygienic departments, it was renamed "Sanitary and Bacteriological Institute." +In 1920, with the opening of [[Epidemiology|epidemiological]], [[Microbiology|microbiological]], [[Parasitology|parasitological]] and sanitary-hygienic departments, it was renamed to the "Sanitary and Bacteriological Institute." -In 1938, the Institute was divided into two parts: scientific and manufacturing. It was renamed "Ukrainian Institute of Epidemiology and Microbiology." At this time, the staff consisted of 250 employees.<ref>{{Cite web|url=http://www.imv.kiev.ua/index.php/en/institute/history#targetText=On%20May%2031,%201928%20by,Ukraine)%20was%20opened%20in%20Kyiv.|title=History|website=www.imv.kiev.ua|access-date=2019-08-31}}</ref> +In 1938, the Institute was divided into two parts: scientific and manufacturing. It was renamed to the "Ukrainian Institute of Epidemiology and Microbiology." At this time, the staff consisted of 250 employees.<ref>{{Cite web|url=http://www.imv.kiev.ua/index.php/en/institute/history#targetText=On%20May%2031,%201928%20by,Ukraine)%20was%20opened%20in%20Kyiv.|title=History|website=www.imv.kiev.ua|access-date=2019-08-31}}</ref> -During the [[World War II]], the Institute was evacuated to [[Kuibyshev]]{{disambiguation needed|date=September 2019}} and continued the research. +During [[World War II]], the Institute was evacuated to [[Kuibyshev]]{{disambiguation needed|date=September 2019}} and continued the research. After the war, manufacturing returned to [[Kiev|Kyiv]]. In 1955, the manufacturing expanded to 12 bacterial drugs. The institute begins to export to [[Europe]], the [[Middle East]], and [[India]].<ref>{{Cite book|url=https://books.google.com.ua/books?id=zfhyDwAAQBAJ&pg=PA145&lpg=PA145&dq=Kuibyshev+Ukrainian+Institute+of+Epidemiology+and+Microbiology&source=bl&ots=G7uk-1TDP2&sig=ACfU3U2KWajAqa_58oOJpXSktkF7Stm7DQ&hl=en&sa=X&ved=2ahUKEwib8r69iZHkAhXpk4sKHRqjAY0Q6AEwBHoECAkQAQ|title=Stalin's Secret Weapon: The Origins of Soviet Biological Warfare|last=Rimmington|first=Anthony|date=2018-11-15|publisher=Oxford University Press|isbn=9780190928858|language=en}}</ref> @@ -41,9 +41,9 @@ In 2005, the company implemented the technology of the virus inactivation by the [[solvent]]/[[detergent]] method in the production of [[immunoglobulins]].<ref>{{Cite web|url=http://www.consilium-medicum.com.ua/issues/1/111/868/|title=CONSILIUM MEDICUM UKRAINA. №1 2014|website=www.consilium-medicum.com.ua|access-date=2019-08-31}}</ref> -In 2005, at the International Forum of Quality, the enterprise receives the [[International Organization for Standardization|ISO]] 9001 certificate.<ref>{{Cite web|url=https://www.biopharma.com.ua/en/company-2/|title=Company|website=biopharma|access-date=2019-08-31}}</ref> +In 2005, at the International Forum of Quality, the enterprise received the [[International Organization for Standardization|ISO]] 9001 certificate.<ref>{{Cite web|url=https://www.biopharma.com.ua/en/company-2/|title=Company|website=biopharma|access-date=2019-08-31}}</ref> In 2009, after a series of changes, reorganizations, and renamings (in 1965, 1978, 1992), PrJSC Biopharma was formed.<ref>{{Cite web|url=https://open4business.com.ua/unit-city-biopharma-and-other-companies-enter-eba/|title=UNIT.CITY, BIOPHARMA AND OTHER COMPANIES ENTER EBA|date=2018-10-07|website=Ukraine open for business|language=en-US|access-date=2019-08-31}}</ref> -In 2012, Horizon Capital and FMO invested into Biopharma for building a new biopharmaceutical production factory equipped with a quality control laboratory.<ref>{{Cite web|url=https://inventure.com.ua/en/news/ukraine/biopharma-is-building-the-scientific-and-production-complex-in-the-value-of-dollar70-mln|title="Biopharma" is building the scientific and production complex in the value of $70 mln|website=inventure.com.ua|language=en|access-date=2019-08-31}}</ref> +In 2012, Horizon Capital and FMO invested in Biopharma for building a new biopharmaceutical production factory equipped with a quality control laboratory.<ref>{{Cite web|url=https://inventure.com.ua/en/news/ukraine/biopharma-is-building-the-scientific-and-production-complex-in-the-value-of-dollar70-mln|title="Biopharma" is building the scientific and production complex in the value of $70 mln|website=inventure.com.ua|language=en|access-date=2019-08-31}}</ref> In 2014, the first phase of the [[Biopharmaceutical]] Research and Manufacturing Complex was launched in [[Bila Tserkva]]. It includes a pharmaceutical plant for the production of medicines, center for research, development and technology, laboratory building for quality control of drugs, warehouses for raw materials and finished products, housing for power systems.<ref>{{Cite web|url=https://ufuture.com/our-companies/biofarma/|title=biopharma|website=Ufuture|language=en-US|access-date=2019-08-31}}</ref> @@ -54,7 +54,17 @@ 2019 (September 19–20) Biopharma jointly with the Ministry of Health of Ukraine held an international forum on blood components and preparations - "Actual issues of industrial production of blood products". Within the framework of the forum, the official opening ceremony of the plasma fractionation plant was held, which became the first such plant in Ukraine and can process up to one million liters of plasma per year. + +In September 2019, the official opening ceremony of the plasma fractionation plant took place, which became the first such plant in Ukraine that can process up to one million liters of plasma per year. <ref>{{Cite web|title=Біла Церква. Завод «Трібо»: від мрії до успіху - YouTube|url=https://www.youtube.com/watch?v=dwVSPa6-i2Y|access-date=2020-08-31|website=www.youtube.com}}</ref> On this occasion, Biopharma together with the [[Ministry of Healthcare (Ukraine)|Ministry of Healthcare of Ukraine]] held an international forum on blood components and preparations - "Current issues of industrial production of blood products". <ref>{{Cite web|title=CoVIg-19 PLASMA ALLIANCE|url=https://www.covig-19plasmaalliance.org/other#recruitment|access-date=2020-08-31|website=www.covig-19plasmaalliance.org}}</ref> <ref>{{Cite web|title=CoVIg-19 PLASMA ALLIANCE BUILDS STRONG MOMENTUM THROUGH EXPANDED MEMBERSHIP AND CLINICAL TRIAL COLLABORATION|url=https://www.takeda.com/newsroom/newsreleases/2020/covig-19-plasma-alliance-builds-strong-momentum-through-expanded-membership-and-clinical-trial-collaboration/|access-date=2020-08-31|website=www.takeda.com|language=en}}</ref> The event was attended by more than 600 professionals from Germany, France, the Netherlands, the United States and other countries. In particular, the forum brought together international experts in the field of clinical and industrial [[Transfusion medicine|transfusiology]]. <ref>{{Cite web|title=У Києві відбувся міжнародний форум з питань компонентів та препаратів крові|url=https://www.ukrinform.ua/rubric-kyiv/2783800-u-kievi-vidbuvsa-miznarodnij-forum-z-pitan-komponentiv-ta-preparativ-krovi.html|access-date=2020-08-31|website=www.ukrinform.ua|language=uk}}</ref> + +In December 2019, Biopharma sold part of the company to the German pharmaceutical manufacturer [[Stada Arzneimittel|STADA]].<ref>{{Cite web|title=STADA Arzneimittel AG - Your Partner in Health|url=https://www.stada.com/|access-date=2020-08-31|website=STADA|language=en}}</ref> This decision was made in view of the fact that STADA will be able to bring investment and new expertise in the production and promotion of medicines. Biopharma's shareholders maintained the production of donor plasma drugs and focused on its development both in Ukraine and abroad. + +Currently, the company is focused on combating the [[COVID-19 pandemic]] and is working in two main areas: + +- Clinical trials of one of the main classic products - the drug Bioven, which is used in the complex treatment of complex [[Bacterial pneumonia|bacterial]] and [[Viral pneumonia|viral pneumonias]]. Potentially, it can also be used for pneumonia caused by COVID-19. + +- The second direction is the development of [[Immunoglobulin|hyperimmune immunoglobulin]] from the plasma of those who became ill with coronavirus. Scientists from different countries are inclined to believe that this drug can potentially be effective for the targeted treatment of patients with COVID-19. To do this, Biopharma joined the CoVIg-19 Plasma Alliance <ref name=":0">{{Cite web|title=CoVIg-19 PLASMA ALLIANCE|url=https://www.covig-19plasmaalliance.org/en-us#recruitment|access-date=2020-08-31|website=www.covig-19plasmaalliance.org}}</ref> <ref name=":1">{{Cite web|title=CoVIg-19 PLASMA ALLIANCE BUILDS STRONG MOMENTUM THROUGH EXPANDED MEMBERSHIP AND CLINICAL TRIAL COLLABORATION|url=https://www.takeda.com/newsroom/newsreleases/2020/covig-19-plasma-alliance-builds-strong-momentum-through-expanded-membership-and-clinical-trial-collaboration/|access-date=2020-08-31|website=www.takeda.com|language=en}}</ref>, which includes 10 world leaders in the production of plasma preparations. === Construction of a new complex === -At the end of 2016, Biopharma started the third stage of the construction – the plant for blood plasma fractionation [9]. In October 2017, after the construction of a new building, the installation of technical equipment was started. At the new facilities, the company will produce [[Albumin]], [[Groundwater remediation|Bioven]], and [[Immunoglobulin]] that help treat diseases caused by [[immunodeficiency]].<ref>{{Cite web|url=http://www.kievoncology.com/nam-ne-bayduzhe-problema-gemofiliyi-v-ukrayini-ta-perspektivi-yiyi-virishennya.html|title=Нам не байдуже: проблема гемофілії в Україні та перспективи її вирішення {{!}} Компью́терная томогра́фия|website=www.kievoncology.com|access-date=2019-08-31|archive-url=https://web.archive.org/web/20190831172028/http://www.kievoncology.com/nam-ne-bayduzhe-problema-gemofiliyi-v-ukrayini-ta-perspektivi-yiyi-virishennya.html|archive-date=2019-08-31|url-status=dead}}</ref><ref>{{Cite web|url=https://delo.ua/business/kak-razvivaetsja-edinstvennyj-v-sng-proizvoditel-preparatov-krov-330430/|title=Как развивается единственный в СНГ производитель препаратов крови — интервью с президентом "Биофарма"|website=delo.ua|language=ru|access-date=2019-08-31}}</ref><ref>{{Cite web|url=https://censor.net.ua/news/340386/v_beloyi_tserkvi_otkryli_noveyishiyi_biofarmatsevticheskiyi_zavod|title=В Белой Церкви открыли новейший биофармацевтический завод|last=Цензор.НЕТ|website=Цензор.НЕТ|language=ru|access-date=2019-08-31}}</ref><ref>{{Cite web|url=https://www.rbc.ua/ukr/news/biofarma-peredala-medikamenty-lecheniya-uchastnikov-1434534839.html|title="Біофарма" передала медикаменти для лікування учасників АТО на 1 млн грн|website=РБК-Украина|language=ru|access-date=2019-08-31}}</ref> +At the end of 2016, Biopharma started the third stage of the construction – the plant for blood plasma fractionation. In October 2017, after the construction of a new building, the installation of technical equipment was started. At the new facilities, the company will produce [[Albumin]], [[Groundwater remediation|Bioven]], and [[Immunoglobulin]] that help treat diseases caused by [[immunodeficiency]].<ref>{{Cite web|url=http://www.kievoncology.com/nam-ne-bayduzhe-problema-gemofiliyi-v-ukrayini-ta-perspektivi-yiyi-virishennya.html|title=Нам не байдуже: проблема гемофілії в Україні та перспективи її вирішення {{!}} Компью́терная томогра́фия|website=www.kievoncology.com|access-date=2019-08-31|archive-url=https://web.archive.org/web/20190831172028/http://www.kievoncology.com/nam-ne-bayduzhe-problema-gemofiliyi-v-ukrayini-ta-perspektivi-yiyi-virishennya.html|archive-date=2019-08-31|url-status=dead}}</ref><ref>{{Cite web|url=https://delo.ua/business/kak-razvivaetsja-edinstvennyj-v-sng-proizvoditel-preparatov-krov-330430/|title=Как развивается единственный в СНГ производитель препаратов крови — интервью с президентом "Биофарма"|website=delo.ua|language=ru|access-date=2019-08-31}}</ref><ref>{{Cite web|url=https://censor.net.ua/news/340386/v_beloyi_tserkvi_otkryli_noveyishiyi_biofarmatsevticheskiyi_zavod|title=В Белой Церкви открыли новейший биофармацевтический завод|last=Цензор.НЕТ|website=Цензор.НЕТ|language=ru|access-date=2019-08-31}}</ref><ref>{{Cite web|url=https://www.rbc.ua/ukr/news/biofarma-peredala-medikamenty-lecheniya-uchastnikov-1434534839.html|title="Біофарма" передала медикаменти для лікування учасників АТО на 1 млн грн|website=РБК-Украина|language=ru|access-date=2019-08-31}}</ref> The opening of the new complex took place in summer 2018. [[Vasyl Khmelnytsky|Mr. Khmelnytsky]] and his partners invested $42 million in the research and production facility.<ref>{{Cite web|url=https://112.international/ukraine-top-news/vasyl-khmelnytsky-and-partners-invest-42-mln-in-biopharma-blood-processing-plant-30404.html|title=Vasyl Khmelnytsky and partners invest $42 mln in Biopharma blood processing plant|website=112.international|language=en-US|access-date=2019-08-31}}</ref> @@ -66,4 +76,29 @@ In 2017, as part of a public-private partnership, Biopharma invested over $3.5 million in the reconstruction and modernization of the [[Sumy]] Regional Blood Service Center.<ref>{{Cite web|url=http://sumynews.com/news-and-ideas/society/11290/sumskyi-tsentr-krovi-pryklad-dlia-vsiiei-ukrainy.html|title=Сумський центр крові – приклад для всієї України — SumyNews|last=SumyNews|website=sumynews.com|language=uk-ua|access-date=2019-08-31}}</ref><ref>{{Cite web|url=https://ukurier.gov.ua/uk/articles/shob-imunoglobulinu-bulo-vdostal/|title=Щоб імуноглобуліну було вдосталь|last=ВЕРТІЛЬ|first=Олександр|date=2017-03-17|website=Урядовий Кур’єр|access-date=2019-08-31}}</ref><ref>{{Cite web|url=http://dls.gov.ua/news/%D1%81%D1%83%D0%BC%D1%81%D1%8C%D0%BA%D0%B8%D0%B9-%D0%BE%D0%B1%D0%BB%D0%B0%D1%81%D0%BD%D0%B8%D0%B9-%D1%86%D0%B5%D0%BD%D1%82%D1%80-%D1%81%D0%BB%D1%83%D0%B6%D0%B1%D0%B8-%D0%BA%D1%80%D0%BE%D0%B2%D1%96-2/|title=Сумський обласний центр служби крові відвідала Голова Держлікслужби : Держлікслужба|website=dls.gov.ua|access-date=2019-08-31}}</ref><ref>{{Cite web|url=https://www.unian.net/society/1931796-biofarma-trebuet-razobratsya-s-neprozrachnoy-zakupkoy-lekarstv-provedennoy-proon.html|title="Биофарма" требует разобраться с непрозрачной закупкой лекарств, проведенной ПРООН|website=www.unian.net|language=ru|access-date=2019-08-31}}</ref> It is the first blood center in Ukraine certified according to the international standard ISO 9001: 2015.<ref>{{Cite web|url=http://www.golos.com.ua/article/301813|title=Дарувати шанс на одужання|website=www.golos.com.ua|language=uk|access-date=2019-08-31}}</ref> + +In 2017, Biopharma launched an all-Ukrainian [[Welfare|social program]] “We do care. We are together", aimed at improving the quality of life of patients with hemophilia in Ukraine<ref>{{Cite web|date=2017-12-28|title=Білоцерківський завод "Біофарма" є єдиним виробником ліків від гемофілії в Україні {{!}} Моя Київщина|url=https://web.archive.org/web/20171228072048/http://mykyivregion.com.ua/2017/04/20/kompaniya-biofarma-kostyantina-yefimenka-yedina-v-ukrayini-sho-viroblyaye-liki-vid-gemofiliyi/|access-date=2020-08-31|website=web.archive.org}}</ref>. In the same year, the company provided charitable assistance to medical institutions of Kyiv region in the amount of UAH 1 million. The company also intends to build 10 modern donor plasma collection centers throughout Ukraine<ref>{{Cite web|last=bc-news|title="Біофарма" повністю забезпечить хворих на гемофілію необхідними ліками|url=http://bc-news.com.ua/podiji/item/2351-biofarma-povnistiu-zabezpechyt-khvorykh-na-hemofiliiu-v-ukraini-neobkhidnymy-likamy|access-date=2020-08-31|website=БЦ News|language=uk-ua}}</ref> <ref>{{Cite web|title=Компания|url=https://www.moirebenok.ua/toddler/zdorove-toddler/kompaniya-biofarma-delaet-svoj-vklad-v-reshenie-problemy-gemofilii-v-ukraine/|access-date=2020-08-31|website=www.moirebenok.ua|language=ru}}</ref>. + +In March 2018, Biopharma initiated public discussions and held a series of meetings with representatives of the All-Ukrainian Hemophilia Society, the World Hemophilia Federation, and the Children with Hemophilia Charitable Foundation.<ref>{{Cite web|title=Запроваджуємо ноу-хау: виробництво ліків – під громадський контроль!|url=https://www.ukrinform.ua/rubric-economy/2424887-zaprovadzuemo-nouhau-virobnictvo-likiv-pid-gromadskij-kontrol.html|access-date=2020-08-31|website=www.ukrinform.ua|language=uk}}</ref> As a result, a Memorandum of Cooperation was concluded and signed, which makes it possible to implement a system of public control over the production of the drug for patients with hemophilia "BioClot A" <ref>{{Cite news|last=Astaforova-Yatsenko|first=Nina|date=May 16, 2020|title=Children with Hemophilia Cheritable Foudation|work=Foundation Memorandum|url=http://hemokids.org.ua/wp-content/uploads/2018/03/Memorandum_skan.pdf|url-status=live|access-date=}}</ref>. Work continues in this direction, in particular, within the framework of the signed contract, the company sent drugs for control to Germany.<ref>{{Cite web|title=Biopharma|url=https://www.facebook.com/biopharma.ua/posts/2384121858276010|access-date=2020-08-31|website=www.facebook.com|language=en}}</ref> + +In May 2020, the company decided to change the standards of donor testing. Therefore, all donors are tested for the presence of [[HIV]], [[hepatitis B]] and [[Hepatitis C|C]] by [[Nucleic acid test|NAT]], as well as the presence of antibodies to COVID-19 by [[ELISA]] on high-precision Swiss test systems ROCHE. + +Biopharma is actively developing the [[Donation|culture of donation]] in Ukraine. The company attracts stars and the public, in particular, the famous Ukrainian singer who supports the culture of donation - [[Oleh Vynnyk]]<ref>{{Cite web|date=2020-07-30|title=Сміливий Олег Винник у розстібнутій сорочці показав, як здав кров|url=https://tsn.ua/glamur/smiliviy-oleg-vinnik-u-rozstibnutiy-sorochci-pokazav-yak-zdav-krov-1595812.html|access-date=2020-08-31|website=ТСН.ua|language=uk}}</ref>. Biopharma also cooperates with donor organizations such as DonorUA <ref>{{Cite web|title=ДонорUA. Здай кров - врятуй життя!|url=https://donor.ua/|access-date=2020-08-31|website=ДонорUA|language=uk}}</ref> and NOVA KROV<ref>{{Cite web|title=NOVA КРОВ|url=https://www.facebook.com/novakrov1/|access-date=2020-08-31|website=www.facebook.com|language=en}}</ref>. Thus, on the basis of the company's center in the city of [[Sumy]], a record of Ukraine was registered<ref>{{Cite web|title=Донори крові "прописали" Суми у Книзі рекордів України|url=https://www.ukrinform.ua/rubric-regions/2526279-donori-krovi-propisali-sumi-u-knizi-rekordiv-ukraini.html|access-date=2020-08-31|website=www.ukrinform.ua|language=uk}}</ref>: the largest number of blood donations per thousand population was recorded there. On average in Ukraine, the rate of donations per thousand population is about 14, and in Sumy this figure is 190. This is almost twice as much as, for example, in the United States. + +At the end of July 2020, the first Biopharma Plasma center was opened in [[Cherkasy]]. The company leased the obsolete regional blood center and turned it into a high-tech progressive European institution. They installed modern equipment and created the most comfortable conditions for both donors and employees.<ref>{{Cite web|title=Олег Винник став донором крові і закликав долучитися до доброї справи інших - YouTube|url=https://www.youtube.com/watch?v=OfzjIRgu8rI&feature=youtu.be&fbclid=IwAR038Gb6Kd-hGbD73wBYeTBpYQ5SZ9KszUiKhOIcYa4-i23-ggB9Kdssrcs|access-date=2020-08-31|website=www.youtube.com}}</ref><ref>{{Cite web|last=Gazeta.ua|date=2020-07-29|title=Олег Винник здав плазму для порятунку українців від Covid-19|url=https://gazeta.ua/articles/health/_oleg-vinnik-zdav-plazmu-dlya-poryatunku-ukrayinciv-vid-covid19/976862|access-date=2020-08-31|website=Gazeta.ua|language=uk}}</ref><ref>{{Cite web|title=Костянтин Єфименко: Інноваційні рішення в галузі служби крові: пацієнту не потрібно шукати донорів|url=https://www.obozrevatel.com/ukr/society/innovatsijni-rishennya-v-galuzi-sluzhbi-krovi-patsientu-ne-potribno-shukati-donoriv.htm|access-date=2020-08-31|website=OBOZREVATEL|language=uk}}</ref> + +== The company's activities during the COVID-19 pandemic == +In March 2020, in cooperation with pharmaceutical companies from other countries, Biopharma will begin the development of drugs based on the [[blood plasma]] of people who have relapsed into COVID-19.<ref>{{Citation|title=Компанія «Біофарма», яка працює в Україні, долучилася до світової ініціативи розробки ліків від Ковід-19. Відео|url=https://ukrainian.voanews.com/a/biofarma/5420244.html|language=uk|access-date=2020-08-31}}</ref><ref>{{Cite web|title=Про імуноглобуліни, донорство плазми крові та ліки від коронавірусу — розмова з президентом «Біофарми»|url=https://hromadske.ua/posts/pro-imunoglobulini-donorstvo-plazmi-krovi-ta-liki-vid-koronavirusu-rozmova-z-prezidentom-biofarmi|access-date=2020-08-31|website=hromadske.ua|language=uk}}</ref> + +At the end of March 2020, Biopharma helped the laboratory of the [[Ministry of Healthcare (Ukraine)|Center for Public Health of Ukraine of the Ministry of Healthcare]] to establish a national reference laboratory for the detection of coronavirus. The equipment purchased by Biopharma will allow quickly and according to modern methods to determine the presence or absence of coronavirus pathogens in the obtained samples.<ref>{{Cite web|date=2020-03-23|title=UFUTURE AND BIOPHARMA SUBMIT COMPLEXES FOR DETECTION OF COVID-19 TO PUBLIC HEALTH CENTER|url=https://open4business.com.ua/ufuture-and-biopharma-submit-complexes-for-detection-of-covid-19-to-public-health-center/|access-date=2020-08-31|website=Ukraine open for business|language=en-US}}</ref><ref>{{Cite web|title=Обладнання для лікарень і продукти для пенсіонерів: як бізнес допомагає боротися з COVID-19|url=https://www.epravda.com.ua/news/2020/04/3/658946/|access-date=2020-08-31|website=Економічна правда|language=uk}}</ref><ref>{{Citation|title=Понад 2 000 тестів за добу - нове обладнання для визначення коронавірусу|url=https://www.facebook.com/biopharma.ua/videos/%D0%BF%D0%BE%D0%BD%D0%B0%D0%B4-2-000-%D1%82%D0%B5%D1%81%D1%82%D1%96%D0%B2-%D0%B7%D0%B0-%D0%B4%D0%BE%D0%B1%D1%83-%D0%BD%D0%BE%D0%B2%D0%B5-%D0%BE%D0%B1%D0%BB%D0%B0%D0%B4%D0%BD%D0%B0%D0%BD%D0%BD%D1%8F-%D0%B4%D0%BB%D1%8F-%D0%B2%D0%B8%D0%B7%D0%BD%D0%B0%D1%87%D0%B5%D0%BD%D0%BD%D1%8F-%D0%BA%D0%BE%D1%80%D0%BE%D0%BD%D0%B0%D0%B2%D1%96%D1%80%D1%83%D1%81%D1%83/519853105391740/|language=en|access-date=2020-08-31}}</ref> In March 2020, the laboratory has already analyzed hundreds of samples and thus became a flagship in the fight against the spread of coronavirus in Ukraine.<ref>{{Cite web|title=Обладнання для лікарень і продукти для пенсіонерів: як бізнес допомагає боротися з COVID-19|url=https://www.epravda.com.ua/news/2020/04/3/658946/|access-date=2020-08-31|website=Економічна правда|language=uk}}</ref> + +In April 2020, Biopharma was the first in Ukraine to start collecting plasma from people who had recovered from COVID-19. Free tests for the presence of antibodies to coronavirus are conducted for all donors, not just those who have been cured of this disease. Plasma is collected from donors by [[Plasmapheresis|hardware plasmapheresis]]. In Ukraine, this technology is used on a regular basis only in Biopharma plasma centers. <ref>{{Cite web|date=2020-05-27|title=CAM reliability and experience for fighting Covid-19|url=http://www.campackaging.it/cam-reliability-and-experience-for-fighting-covid-19|access-date=2020-08-31|website=CAM Automatic Machines|language=it-IT}}</ref><ref>{{Cite web|last=Цензор.НЕТ|title="Биофарма" будет производить иммуноглобулин из плазмы крови переболевших Covid-19, - Ефименко|url=https://censor.net/ru/news/3190648/biofarma_budet_proizvodit_immunoglobulin_iz_plazmy_krovi_perebolevshih_covid19_efimenko|access-date=2020-08-31|website=Цензор.НЕТ|language=ru}}</ref><ref>{{Cite web|title=Biopharma начинает тестировать на антитела к COVID-19|url=https://interfax.com.ua/news/general/657603.html|access-date=2020-08-31|website=Интерфакс-Украина|language=ru}}</ref><ref>{{Cite web|date=2020-04-29|title=У Сумах охочих почали тестувати на наявність антитіл до коронавірусу: чому цінна плазма перехворілих|url=https://tsn.ua/ukrayina/u-sumah-ohochih-pochali-testuvati-na-nayavnist-antitil-do-koronavirusu-chomu-cinna-plazma-perehvorilih-1537779.html|access-date=2020-08-31|website=ТСН.ua|language=uk}}</ref><ref>{{Cite web|title=Черкащанка, яка поборола коронавірус, здала плазму для виготовлення ліків - YouTube|url=https://www.youtube.com/watch?v=YeVAB9oZya4|access-date=2020-08-31|website=www.youtube.com}}</ref><ref>{{Cite web|title=У Дніпрі збиратимуть плазму крові людей, які одужали від коронавірусу|url=https://glavcom.ua/news/u-dnipri-zbiratimut-plazmu-krovi-lyudey-yaki-oduzhali-vid-koronavirusu-678499.html?fbclid=IwAR2fDJriKI1MNksjwnMKMCPIUiIQ2cjGAGOKfhWe7sh9svJ5ytIf65-X4W8|access-date=2020-08-31|website=glavcom.ua|language=uk}}</ref> + +Biopharma has joined the CoVIg-19 Plasma Alliance.<ref name=":0" /><ref name=":1" /> The purpose of its activity is to develop drugs for COVID-19. World leaders in the production of [[Blood plasma|plasma drugs]] have joined forces to accelerate the development and production of [[Immunoglobulin|hyperimmune immunoglobulin]]. The purpose of the drug is to treat patients with complicated COVID-19. The joint action was initiated by [[CSL Behring]] (USA) and [[Takeda Pharmaceutical Company]] (Japan). They have already been joined by Biotest (Germany), [[Bio Products Laboratory]] (UK), LFB (France) and [[Octapharma]] (Switzerland). Biopharma is the only Ukrainian company that is a member of this International Alliance.<ref name=":0" /><ref name=":1" /><ref>{{Cite web|title=Biopharma приєдналася до міжнародного альянсу з розробки гіперімунного імуноглобуліну для лікування COVID-19|url=https://ua.interfax.com.ua/news/pharmacy/655794.html|access-date=2020-08-31|website=Інтерфакс-Україна|language=uk}}</ref><ref>{{Cite web|date=2020-04-21|title=Biopharma приєдналась до міжнародного альянсу з розробки ліків від COVID-19|url=https://ufuture.com/uk/biopharma-priyednalas-do-mizhnarodnogo-alyansu-z-rozrobki-likiv-vid-covid-19/|access-date=2020-08-31|website=UFuture|language=uk-UA}}</ref><ref>{{Cite web|last=СпецКор|title=Biopharma приєдналась до міжнародного альянсу з розробки ліків від COVID-19 — СпецКор|url=http://spec-kor.com.ua/news/3477-biopharma-pryiednalas-do-mizhnarodnoho-aliansu-z-rozrobky-likiv-vid-covid19.html|access-date=2020-08-31|website=spec-kor.com.ua|language=uk-ua}}</ref> At the end of July 2020, a round table was held in the [[United States]] with the participation of the US President [[Donald Trump]]. During the event, members of the International CoVIg-19 Alliance reported on the pace of drug development, and the US President called on the public to donate "covid" plasma.<ref>{{Cite web|title=https://twitter.com/whitehouse/status/1288919400960188422|url=https://twitter.com/whitehouse/status/1288919400960188422|access-date=2020-08-31|website=Twitter|language=en}}</ref> + +In May 2020, Biopharma received official permission to conduct clinical trials of the classic drug Bioven, which is potentially effective in the treatment of COVID-19.<ref>{{Cite web|title=Наказ МОЗ України від 04.05.2020 № 1038 "Про проведення клінічного випробування лікарського засобу, призначеного для здійснення заходів, спрямованих на запобігання виникненню та поширенню, локалізацію та ліквідацію коронавірусної хвороби (COVID-19)"|url=https://moz.gov.ua/article/ministry-mandates/nakaz-moz-ukraini-vid-04052020--1038-pro-provedennja-klinichnogo-viprobuvannja-likarskogo-zasobu-priznachenogo-dlja-zdijsnennja-zahodiv-sprjamovanih-na-zapobigannja-viniknennju-ta-poshirennju-lokalizaciju-ta-likvidaciju-koronavirusnoi-hvorobi-covid-19?fbclid=IwAR0NBsYec0jP8q-IpDAGOQTaQLjgZabtji4LuqDC1arnYo5TmCmPYRqnuYM|access-date=2020-08-31|website=moz.gov.ua}}</ref> Already in August, the influential American web resource [[ClinicalTrials.gov]] published clinical trials of the drug Bioven.<ref>{{Cite journal|last=Biopharma Plasma LLC|date=2020-08-04|title=An Open-label Multicenter Randomized Trial to Evaluate the Efficacy of Bioven, Manufactured by Biopharma Plasma, LLC, in Complex Therapy of Patients With Pneumonia Induced by COVID-19 / SARS-CoV-2|url=https://clinicaltrials.gov/ct2/show/NCT04500067}}</ref> During the research, Ukrainian and international experts noted that Bioven reduces the severity of the cytokine storm and stabilizes the condition of critically ill patients. In all who took Bioven, there was a stabilization of the general condition within 2 days after administration of the drug with a subsequent reduction in the manifestations of respiratory failure.<ref>{{Cite journal|last=Biopharma Plasma LLC|date=2020-08-04|title=An Open-label Multicenter Randomized Trial to Evaluate the Efficacy of Bioven, Manufactured by Biopharma Plasma, LLC, in Complex Therapy of Patients With Pneumonia Induced by COVID-19 / SARS-CoV-2|url=https://clinicaltrials.gov/ct2/show/NCT04500067}}</ref> + +Biopharma intends to invest $ 7 million in the construction of a new office and laboratory complex in [[Bila Tserkva]]. There are input and output control laboratories, R&D laboratory, and coworking laboratory. The company plans to provide it to various applicants to work on research projects. Design has already begun, and construction is scheduled to begin in the fall of 2020. <ref>{{Cite web|title="Біофарма" інвестує у будівництво нового лабораторного комплексу $7 млн|url=https://ua.interfax.com.ua/news/pharmacy/669169.html|access-date=2020-08-31|website=Інтерфакс-Україна|language=uk}}</ref> + +In June 2020, more than 12,000 people have been tested with high-precision Roche systems in Biopharma plasma centers. Antibodies to COVID-19 were detected in 58 Ukrainians. The rate is 0.46% of the total number of donors analyzed.<ref>{{Cite web|title=Biopharma|url=https://www.facebook.com/biopharma.ua/posts/3254142167940637|access-date=2020-08-31|website=www.facebook.com|language=en}}</ref> == References == '